AbbVie recently filed a lawsuit against the U.S. Department of Health and Human Services, protesting the inclusion of its botulinum toxin product Botox in the Medicare drug price negotiation list under the Inflation Reduction Act.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BlackRock CIO Dumps Stocks for High-Grade Bonds. Here’s Why
A HYPE whale transferred 266,600 tokens worth approximately $24.29 million to exchanges within three days.
Former senior official of the Bank of Japan predicts that a rate hike in October is "a real possibility," with a very low probability of postponement until next year
A former executive director in charge of monetary policy at the Bank of Japan stated that the Bank of Japan may raise its benchmark interest rate for the second consecutive month at the October policy meeting, which would be earlier than most economists expect.
Falling Oil Could Trigger a 10% Stock Market Rally, Says Wall Street Strategist
Crypto prices
More
